News und Analysen
VALBIOTIS gewährt dem neuen Aktionär AMIRAL GESTION Kapitalzugang zu einem Preis von 4,50 € pro Aktie, entsprechend einer Prämie von 5,4% im Vergleich zum Börsenschlusskurs vom 16. Juli 2020
VALBIOTIS (Paris:ALVAL) (FR0013254851 – ALVAL, für den französischen PEA/KMU qualifiziert), ein Forschungs- und Entwicklungsunternehmen mit Schwerpunkt auf wissenschaftlicher Innovation zur
Nanobiotix Announces Revenue for Second Quarter 2020 and First Half Year 2020
Regulatory News:
NANOBIOTIX (Paris:NANO) (Euronext : NANO – ISIN : FR0011341205 – the ‘‘Company’’), a late clinical-stage nanomedicine company pioneering new approaches to the treatment of
Puma Biotechnology Licensing Partner Specialised Therapeutics Receives Marketing Approval in Malaysia for NERLYNX® (neratinib) for Extended Adjuvant Treatment of Early Stage HER2-Positive Breast Cancer
Puma Biotechnology, Inc. (NASDAQ: PBYI), a biopharmaceutical company, announced that its licensing partner Specialised Therapeutics Asia (STA) has received marketing approval of NERLYNX®
Isturisa® Is Now Available as a Medical Treatment for Cushing's Syndrome in Germany
Cortisol synthesis inhibitor osilodrostat (Isturisa®) is now available in Germany as of July 15, 2020, as a promising new therapy option for medical treatment of adult patients with endogenous
VALBIOTIS meldet erste Visite des ersten Patienten in der internationalen, klinischen Phase-II/III-Studie REVERSE-IT zu TOTUM-63 zur Reduktion von Risikofaktoren für Typ-2-Diabetes
VALBIOTIS (Paris:ALVAL) (FR0013254851 - ALVAL, PEA/SME-qualifiziert), ein Forschungs- und Entwicklungsunternehmen mit Schwerpunkt auf wissenschaftlicher Innovation zur Vorbeugung und Bekämpfung von
Sensorion Hosting Key Opinion Leader Call with Dr. Michael Hoffer on Sudden Sensorineural Hearing Loss and SENS-401 as a Potential Treatment Option on July 23, 2020
Regulatory News:
Sensorion (FR0012596468 – ALSEN) a pioneering, clinical-stage biotechnology company which specializes in the development of novel therapies to restore, treat and prevent within
VALBIOTIS Announces the First Patient First Visit in the International Phase II/III REVERSE-IT Clinical Study on TOTUM-63 to Reduce Type 2 Diabetes Risk Factors
Regulatory News:
VALBIOTIS (Paris:ALVAL) (FR0013254851 - ALVAL, PEA/SME eligible) a Research & Development company committed to scientific innovation for preventing and combating metabolic
Novocure Announces Clinical Trial Collaboration with MSD to Evaluate Tumor Treating Fields Together with KEYTRUDA® (pembrolizumab) in Non-Small Cell Lung Cancer
Novocure (NASDAQ: NVCR) today announced it has entered into a clinical trial collaboration agreement with MSD (a tradename of Merck & Co., Inc.), through a subsidiary, to develop Tumor Treating
MorphoSys: Milliardendeals?!
Bereits gestern Abend, nachbörslich, veröffentlichte das deutsche Biotechnologieunternehmen MorphoSys (WKN: 663200) eine bedeutende Ad hoc-Meldung. Die Aktie reagiert entsprechend.
Demnach hat der
Charles River Laboratories Schedules Second-Quarter 2020 Earnings Release and Conference Call
Charles River Laboratories International, Inc. (NYSE: CRL) will release second-quarter 2020 financial results on Wednesday, August 5th, before the market opens. A conference call has been scheduled
IMV Updates Rapid Progress on COVID-19 Vaccine Program
IMV Inc. (Nasdaq: IMV; TSX: IMV), a clinical-stage biopharmaceutical company pioneering a novel class of cancer immunotherapies and vaccines against infectious diseases, provides further details
Pfizer and BioNTech Granted FDA Fast Track Designation for Two Investigational mRNA-based Vaccine Candidates Against SARS-CoV-2
Pfizer Inc. (NYSE: PFE) and BioNTech SE (Nasdaq: BNTX, “BioNTech”) today announced that two of the companies’ four investigational vaccine candidates from their BNT162 mRNA-based vaccine program
Quantum Genomics Enrolls First Patient in Its Pivotal Phase III FRESH Trial of Firibastat in Difficult-to-treat and Resistant Hypertension
Quantum Genomics (Euronext Growth - FR0011648971 - ALQGC), a biopharmaceutical company specializing in developing a new drug class that directly targets the brain to treat difficult-to-treat and
Qiagen: Muss Thermo-Fisher jetzt nachbessern?
Größter Gewinner im MDAX ist heute die Aktie des deutsch-niederländischen Biotechausrüsters Qiagen (WKN: A2DKCH). Grund hierfür sind die bereits gestern Abend überraschend vorgelegten vorläufigen
Puma Biotechnology Reports Inducement Awards Under Nasdaq Listing Rule 5635(c)(4)
Puma Biotechnology, Inc. (NASDAQ: PBYI), a biopharmaceutical company, announced that on July 8, 2020 the Compensation Committee of Puma’s Board of Directors approved the grant of inducement
Pfizer Pledges $100 Million to New Industry Fund to Help Fight Growing Threat of Antimicrobial Resistance
Pfizer Inc. (NYSE: PFE) announced today it has pledged $100 million to the new Antimicrobial Resistance (AMR) Action Fund, which launched today, to help address the significant global public health
Transgene and Hypertrust Patient Data Care Announce Successful Go-Live of the World’s First Blockchain Solution for Clinical Trials of Personalized Healthcare
Regulatory News:
Transgene (Paris:TNG) and Hypertrust Patient Data Care today announced as a world premiere the first productive blockchain solution for clinical trials of personalized
THERANEXUS ANNOUNCES ITS CASH POSITION AS OF 30 JUNE 2020 AND IMPLEMENTATION OF A MANDATORY CONVERTIBLE BOND FACILITY
- Pro forma cash of €13.3 M at 30 June 2020
- Implementation of financing for a maximum total of €4.2 million over 12 months through the issuance of warrants to subscribe mandatory convertible bonds
VALBIOTIS: Start der internationalen klinischen Studie Phase-II/III-REVERSE-IT zu TOTUM-63 zur Verringerung der Risikofaktoren für Typ-2-Diabetes genehmigt
VALBIOTIS (FR0013254851 - ALVAL / PEA/SME-qualifiziert), ein Forschungs- und Entwicklungsunternehmen mit Schwerpunkt auf wissenschaftlicher Innovation zur Vorbeugung und Bekämpfung von
Xencor and Atreca Enter Strategic Collaboration to Discover, Develop and Commercialize Novel T Cell Engaging Bispecific Antibodies
Xencor, Inc. (NASDAQ: XNCR), a clinical-stage biopharmaceutical company developing engineered monoclonal antibodies for the treatment of cancer and autoimmune diseases, and Atreca, Inc. (Atreca)
Novocure Announces Over 100 Physicians in the U.S. Now Certified to Prescribe Optune Lua™
Novocure (NASDAQ: NVCR) today announced that over 100 physicians from more than 50 cancer treatment centers in the U.S. are now certified to prescribe Optune Lua, which is approved for the
VALBIOTIS: Authorization to Launch the International Phase II/III REVERSE-IT Clinical Study on TOTUM-63, to Reduce Type 2 Diabetes Risk Factors
Regulatory News:
VALBIOTIS (FR0013254851 - ALVAL / PEA/SME eligible), a Research & Development company committed to scientific innovation, for preventing and combating metabolic diseases
Novocure Enrolls Last Patient in HEPANOVA Trial Testing Tumor Treating Fields in Combination with Sorafenib in Advanced Liver Cancer
Novocure (NASDAQ: NVCR) today announced that the last patient has been enrolled in the HEPANOVA trial, a phase 2 pilot trial testing Tumor Treating Fields in combination with sorafenib in patients
Otonomy: Tinnitus-Studie liefert glänzende Ergebnisse!
Starke Tinnitus-Daten schicken die Aktie von Otonomy (WKN: A119VZ) nachbörslich in die Höhe. Im No Brainer Club reißt die Erfolgsserie nicht ab. Wie geht es jetzt weiter?
Mit der Aktie von Otonomy
Sensorion Appoints Dr Edwin Moses, Former Ablynx CEO, as Chairman of the Board
Regulatory News:
Sensorion (Paris:ALSEN) (FR0012596468 – ALSEN) a pioneering, clinical-stage biotechnology company which specializes in the development of novel therapies to restore, treat and